There is no body of controlled safety trials for IV NAD⁺ comparable to what exists for oral precursors, and the product is compounded — not FDA-approved and not reviewed by the FDA for safety or quality before administration. People receiving infusions commonly report flushing, chest tightness, nausea and cramping during the drip, which clinics manage by slowing the rate. Those are practice reports, not trial findings.

Can NAD⁺ be harmful?

The oral precursor trials that have been run did not find harm, but they are small and short — dozens of people over weeks. That is reassuring about common, short-term effects and says little about rare harms or years of use. For injectable and IV formats there is not enough controlled data to answer the question either way, and an absence of evidence is a risk you carry rather than a clean bill of health.

What should I tell my doctor?

Name the format and route (capsule, injection, IV), the compound (NR, NMN, or NAD⁺ itself), the dose in milligrams, and how often you take it. If your provider does not publish the dose, say that too — it is the most common gap in this category and it makes the product genuinely hard to assess.

← Research

Safety

NAD⁺ side effects: what the safety trials show, and where there are none

Oral NAD⁺ precursors have been through dedicated safety trials and were well tolerated. Injections and IV drips have no comparable evidence base at all — and that difference is the one worth understanding before you choose a format.

Laura BennettSeptember 20266 min read

The honest answer to “does NAD⁺ have side effects” depends almost entirely on which NAD⁺ you mean, and the gap between the formats is much larger than the marketing suggests. Oral precursors have been through dedicated safety trials. Injectable and IV NAD⁺ have not.

Oral precursors: the format with actual safety data

Nicotinamide riboside has been tested specifically for safety rather than only for effect. In a randomized, double-blind, placebo-controlled trial in healthy overweight adults, there was no difference in adverse events between NR and placebo, or between different NR doses^[1]. Worth knowing who ran it: that trial was authored by ChromaDex Spherix Consulting, the consulting arm of the company that sells the ingredient. That does not make the result wrong, and it is the kind of thing you should be told rather than left to discover.

A separate high-dose safety trial in Parkinson’s disease tested NR well above typical supplement doses ^[2]. For NMN, a trial of 1,250 mg once daily for up to four weeks in 31 healthy adults aged 20–65 reported no adverse events over the study period and concluded the dose was safe and well tolerated ^[3]. A longer-running NMN study looked at metabolism and sleep alongside safety^[4].

Two caveats that matter more than they sound. These trials are small and short — dozens of people over weeks, not thousands over years. And “no adverse events in 31 people over four weeks” is a genuinely reassuring finding that tells you almost nothing about a rare harm or a multi-year exposure.

Injections, IV and nasal sprays: what is not known

Here the honest answer is uncomfortable. There is no body of controlled safety trials for injectable or IV NAD⁺ comparable to what exists for the oral precursors. The products sold through telehealth are compounded, which means they are not FDA-approved and the FDA has not reviewed them for safety, efficacy or quality before they reach you.

People who receive NAD⁺ infusions commonly describe flushing, chest tightness, nausea and cramping during the drip, which clinics typically manage by slowing the infusion rate. Those are reports from practice rather than findings from controlled trials, and we are labeling them as such rather than dressing them up as evidence.

The absence of trials is not proof of harm. It is an absence of information, and you are the one carrying it. That is a fair thing to weigh against the fact that these are also the most expensive formats.

What to tell a clinician before you start

Bring the specifics, because “I’m taking NAD⁺” is not enough for anyone to advise you properly. Name the format and route (capsule, injection, IV), the compound (NR, NMN, or NAD⁺ itself), the dose in milligrams, and the frequency. If you cannot find the dose because your provider does not publish it, that is worth raising too — it is the single most common gap in this category, and the reason we built a cost-per-milligram calculator that requires you to ask.

NMN carries one extra wrinkle that is regulatory rather than clinical: its status as a lawful dietary supplement ingredient in the United States is unresolved, which affects availability rather than safety.

The short version

Oral precursors have real, if limited, human safety data and were well tolerated in the trials that have been run. Injectable and IV NAD⁺ have no comparable evidence base and are not FDA-reviewed. If safety is what you are weighing, that asymmetry points the same direction the efficacy evidence does — toward the cheapest option, not the most expensive one.

None of this is medical advice, and none of it replaces a clinician who knows your history and your other medications.

Frequently asked

Does NAD⁺ have side effects?: It depends on the format. In dedicated safety trials, oral nicotinamide riboside showed no difference in adverse events versus placebo, and 1,250 mg of NMN daily for up to four weeks was reported as safe and well tolerated in 31 healthy adults. Injectable and IV NAD⁺ have no comparable controlled safety trials, so for those formats the honest answer is that it is not well characterized.
Is IV NAD⁺ safe?: There is no body of controlled safety trials for IV NAD⁺ comparable to what exists for oral precursors, and the product is compounded — not FDA-approved and not reviewed by the FDA for safety or quality before administration. People receiving infusions commonly report flushing, chest tightness, nausea and cramping during the drip, which clinics manage by slowing the rate. Those are practice reports, not trial findings.
Can NAD⁺ be harmful?: The oral precursor trials that have been run did not find harm, but they are small and short — dozens of people over weeks. That is reassuring about common, short-term effects and says little about rare harms or years of use. For injectable and IV formats there is not enough controlled data to answer the question either way, and an absence of evidence is a risk you carry rather than a clean bill of health.
What should I tell my doctor?: Name the format and route (capsule, injection, IV), the compound (NR, NMN, or NAD⁺ itself), the dose in milligrams, and how often you take it. If your provider does not publish the dose, say that too — it is the most common gap in this category and it makes the product genuinely hard to assess.

Sources

[1] Conze D, Brenner C, Kruger CL. (Funding/affiliation: ChromaDex Spherix Consulting — the ingredient manufacturer) (2019). Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults Scientific Reports. PMID 31278280
[2] Berven H, Kverneng S, Sheard E, et al. (2023). NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease Nature Communications. PMID 38016950
[3] Fukamizu Y, Uchida Y, Shigekawa A, et al. (2022). Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women Scientific Reports. PMID 36002548
[4] Yamaguchi S, Irie J, Mitsuishi M, et al. (2024). Safety and efficacy of long-term nicotinamide mononucleotide supplementation on metabolism, sleep, and nicotinamide adenine dinucleotide biosynthesis in healthy, middle-aged Japanese men Endocrine Journal. PMID 38191197